<DOC>
	<DOCNO>NCT02138383</DOCNO>
	<brief_summary>The main purpose study find dose enzalutamide safely give gemcitabine nab-paclitaxel patient advanced pancreatic cancer . Researchers also want find side effect drug give together . This study help find effect tumor combination enzalutamide , gemcitabine nab-paclitaxel . In first part study , different dos enzalutamide test . In second part study , patient start dose enzalutamide .</brief_summary>
	<brief_title>Enzalutamide Combination With Gemcitabine Nab-Paclitaxel Treatment Advanced Pancreatic Cancer</brief_title>
	<detailed_description />
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<criteria>Participants must histologically cytologically confirm pancreatic adenocarcinoma metastatic unresectable . In dose expansion phase , tumor must express Androgen Receptor ( AR ) immunohistochemistry . If â‰¥1 % tumor cell express AR , consider positive trial . Must measurable disease per Response Criteria Solid Tumors ( RECIST ) criteria version 1.1 Eastern Cooperative Oncology Group ( ECOG ) performance status &lt; 2 ( Karnofsky &gt; 60 % ) Life expectancy great 3 month Must normal organ marrow function Prior treatment gemcitabine alone 5Fluorouracil radiation adjuvant therapy allow ; Should receive gemcitabine within 6 month start study treatment ; 5Fluorouracil radiation treatment receive 4 week prior receive study drug . Women childbearing potential men must agree use adequate contraception prior study entry duration study participation . Men treat enrol protocol must also agree use adequate contraception prior study , duration study participation , 4 month completion study treatment . Ability understand willingness sign write informed consent document Prior treatment cytotoxic chemotherapy except adjuvant therapy . Participant receive gemcitabine within 6 month start study treatment . 5Fluorouracil radiation treatment receive 4 week prior receive study drug . May receive investigational agent within 4 week start study treatment study period . Untreated brain leptomeningeal metastasis , include patient continue require glucocorticoid brain leptomeningeal metastasis . History allergic reaction attribute compound similar chemical biologic composition gemcitabine , nabpaclitaxel enzalutamide . Have undergone major surgery within 4 week prior start study treatment . Uncontrolled intercurrent illness include , limited ongoing active infection , symptomatic congestive heart failure , unstable angina pectoris , cardiac arrhythmia , psychiatric illness/social situation would limit compliance study requirement ; history myocardial infarction within 6 month start study treatment . Known history human immunodeficiency virus ( HIV ) infection active hepatitis B hepatitis C Any history seizure . History loss consciousness transient ischemic attack within 12 month start study drug . Women pregnant breast feeding , women/men able conceive unwilling practice effective method birth control Chronic treatment immunosuppressant drug Other malignancy require active treatment Any significant medical condition , laboratory abnormality , psychiatric illness , would prevent participate study , include inability swallow capsule Any active infection control antibiotic Concomitant medication low seizure threshold</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>advanced pancreatic cancer</keyword>
	<keyword>pancreas</keyword>
	<keyword>malignant neoplasm</keyword>
	<keyword>endocrine system</keyword>
</DOC>